PCM
YMAB

Penserra Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Penserra Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-995
Closed -$28K – 1573
2021
Q3 		$28K Buy
995
+5
+0.5% +$158 ﹤0.01% 1199
2021
Q2 		$33K Buy
990
+10
+1% +$321 ﹤0.01% 1084
2021
Q1 		$29K Buy
980
+50
+5% +$2.05K ﹤0.01% 908
2020
Q4 		$46K Buy
930
+588
+172% +$27.2K ﹤0.01% 702
2020
Q3 		$13K Buy
+342
New +$13.6K ﹤0.01% 798

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Penserra Capital Management's YMAB Position: Q4 2021 in Review

Penserra Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2021, closing a stake of 995 shares — an estimated $28K sold.

Penserra Capital Management first reported a position in YMAB in Q3 2020 and held it in 5 quarters. The position peaked at $46K in Q4 2020. 97 funds tracked by Wall St. Rank hold YMAB as of Q4 2021.

  • Penserra Capital Management reported no remaining Y-mAbs Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 995 Y-mAbs Therapeutics shares in Q4 2021, an estimated $28K.
  • Penserra Capital Management first reported a position in Y-mAbs Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Y-mAbs Therapeutics position peaked at $46K in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.